On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

Using an innovative and recently validated animal model of IBS, the researchers showed that opioid delta-receptor agonists can ameliorate stress-induced IBS symptoms by acting on the insular cortex of ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

FDA approves Journavx, a non-opioid medication for moderate to severe acute pain. Learn about its efficacy and side effects.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...